Trial Profile
An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg s.c. with or without previous exposure to systemic therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PROSE
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Nov 2021 Results (n=1629) comparing the disease burden and patient needs at baseline, and patient benefits and satisfaction with secukinumab treatment across Europe, published in the Journal of the European Academy of Dermatology and Venereology.
- 05 Mar 2019 According to a Novartis media release, new data from this study was presented as a late-breaker at American Academy of Dermatology.
- 10 Jul 2018 Status changed from active, no longer recruiting to completed.